Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05351411
What this trial is testing

Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Firat University 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07222956
What this trial is testing

Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Secondary ProgressiveMultiple Sclerosis (MS) Primary Progressive
Moein Amin 20
Testing effectiveness (Phase 2)Study completedNCT01910259
What this trial is testing

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

Who this might be right for
Secondary Progressive Multiple Sclerosis
University College, London 445
Not applicableUnknownNCT04260711
What this trial is testing

Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Amsterdam UMC, location VUmc 130
Testing effectiveness (Phase 2)Study completedNCT03355365
What this trial is testing

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Tisch Multiple Sclerosis Research Center of New York 54
Testing effectiveness (Phase 2)UnknownNCT00298662
What this trial is testing

Combination Therapy of Betaseron-Prograf in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Clinique de sclérose en plaques et neuromusculaire de l'Outaouais 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05147220
What this trial is testing

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 1,000
Large-scale testing (Phase 3)Study completedNCT04411641
What this trial is testing

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Who this might be right for
Non-relapsing Secondary Progressive Multiple Sclerosis
Sanofi 1,131
Early research (Phase 1)Study completedNCT02506751
What this trial is testing

Open-label Study of Liothyronine in MS

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Johns Hopkins University 20
Not applicableStudy completedNCT02403570
What this trial is testing

Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Turku University Hospital 21
Not applicableUnknownNCT05937802
What this trial is testing

Osmotin Plant Protein for Progressive Multiple Sclerosis

Who this might be right for
Progressive Multiple Sclerosis
Ospedale Policlinico San Martino 50
Early research (Phase 1)Ended earlyNCT01435993
What this trial is testing

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 3
Post-approval studies (Phase 4)Study completedNCT04792567
What this trial is testing

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Who this might be right for
Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals 41
Not applicableStudy completedNCT03134573
What this trial is testing

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Who this might be right for
Multiple Sclerosis
Bayer 96
Early research (Phase 1)Not Yet RecruitingNCT07562074
What this trial is testing

Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis

Who this might be right for
Multiple SclerosisDepression - Major Depressive DisorderFatigue
University of Calgary 20
Very early researchTemporarily pausedNCT07146087
What this trial is testing

Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biocells Medical 20
Not applicableStudy completedNCT03424538
What this trial is testing

The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Primary Progressive
Somogy Megyei Kaposi Mór Teaching Hospital 2
Not applicableStudy completedNCT05663853
What this trial is testing

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
LAPIX Therapeutics Inc. 137
Testing effectiveness (Phase 2)Study completedNCT05691192
What this trial is testing

Cognitive Reserve-building Activities in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Rigshospitalet, Denmark 60
Testing effectiveness (Phase 2)Study completedNCT03560739
What this trial is testing

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 284
Next Page